Navigation Links
Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
Date:5/14/2008

Conference Call To Be Held Thursday, May 15, 2008 at 9:00 a.m. Eastern Time

HOPKINTON, Mass., May 14 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended March 31, 2008 and provides further information for fiscal year 2008. Recent highlights include:
- Encouraging 12 month interim results from the Phase I/IIa Cethrin(R)

clinical trial in acute spinal cord injury

- Entry into an option agreement which provides the Company with an

option to amend its Cethrin license to lower milestone payments and

royalty rates in exchange for a fee

- Expansion of sites for the first stage of the Parkinson's or Essential

Tremor, or POET-2, Altropane(R) Phase III clinical trial program

- $5 million raised in March 2008

"Our programs continue to show promising progress," said Peter G. Savas, Chairman and Chief Executive Officer of Alseres. "We are encouraged by the unprecedented sensory and motor recovery seen in patients treated with Cethrin in our Phase I/IIa clinical trial. Key opinion leaders with whom we have spoken are highly impressed by the efficacy findings in the study. Armed with these results and after discussions with regulatory authorities and expert advisors, we were able to reduce the planned size of our Phase IIb clinical trial from 200 patients to a maximum of 100 patients providing us with potential time savings and cost reductions."

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO)

"We plan to start this trial in acute cervical spinal cord injury patients in the seco
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
2. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
6. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
7. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
8. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
10. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
11. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Each year, the Susan G. Komen organization hosts ... for breast cancer. This year, Dr. Mark Deutsch and his ... entertainment sponsor for the 25th annual Susan G. Komen Greater ... Lenox Square Mall. , The Komen organization hopes have 10,000 ... million. Perimeter Plastic Surgery has not only taken on the ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a ... academic center on Wednesday, April 22. , Johnson & Wales ... available by the re-alignment of Interstate-195. JWU’s new academic building, ... Chestnut streets in Providence, is scheduled to be completed in ... land the university purchased in 2012. , “It has long ...
(Date:5/4/2015)... West Orange, NJ (PRWEB) May 04, 2015 ... largest non-profit organization devoted exclusively to funding innovative lymphoma ... series of education programs, outreach initiatives and patient services ... Luncheon at the historic Mayfair Farms in West Orange, ... has raised nearly $500,000 for innovative research programs through ...
(Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 The ... as baby boomers join the ranks of senior citizens ... demand on an already over-burdened healthcare system. Additionally, as ... staff to replace them. Per the U.S. Census Bureau, ... expected to increase 75% by 2050 while those 25 ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4
... Healthcare, Inc., a leader in the field of kidney disease services ... Coplon Extramural Grants. Recipients of these annual grants are young scientists ... Canada who are pursuing innovative kidney disease research projects. ... ...
... MONDAY, Sept. 22 (HealthDay News) -- A new study ... have an underactive thyroid gland that does not cause ... As many as 27 million Americans have some type ... Clinical Endocrinologists; about half of these people are undiagnosed. ...
... new, previously unknown mechanism of immunity suggests that there ... and adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers ... Health (HSPH). The findings, published in the open-access journal ... the development of novel pneumococcal vaccines. (The current vaccine, ...
... portion of sales of popular pink, suitcase ... MIAMI BEACH, Fla., Sept. 22 Nonprofit Charity ... up to provide,support for women diagnosed with breast cancer ... Cancer Awareness Month., Through the ,Dash for a ...
... Medical Policy Will Discuss New Paradigm for Health Plan ... ... WellPoint, Inc., the nation,s,largest health benefits company, today announced Dr. Alan ... Dr. Rosenberg, vice president of Medical Policy,Technology Assessment and Credentialing Programs ...
... of well-being, even death , , MONDAY, Sept. 22 (HealthDay ... comes to opportunities to empathize with the plight of ... While doctors are able to address such concerns as ... skirt "existential" issues, such as questions dealing with life ...
Cached Medicine News:Health News: Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers 2Health News: Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers 3Health News:Low Thyroid Function Linked to Heart Failure Risk 2Health News:Low Thyroid Function Linked to Heart Failure Risk 3Health News:New insights could lead to a better pneumococcal vaccine 2Health News:Nonprofit Charity for Women and Brookstone Dash to Fund Breast Cancer Support 2Health News:WellPoint's Dr. Alan Rosenberg to Address Industry's Top Medical Technology Conference 2Health News:WellPoint's Dr. Alan Rosenberg to Address Industry's Top Medical Technology Conference 3Health News:For Some Doctors, Empathy Is in Short Supply 2Health News:For Some Doctors, Empathy Is in Short Supply 3
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... MUNDELEIN, Ill. , May 4, 2015 ... , with live video and product demonstrations at the ... Radiology imaging equipment such as Kodak and Fuji Cr,s, ... be auctioned at the first event. Various imaging equipment ... www.RadiologyAuction.com . After years of buying ...
(Date:5/4/2015)... , May 4, 2015  Oncobiologics, Inc., a ... antibody (mAb) biosimilars, has completed the construction of ... headquarters in Cranbury, New Jersey ... facility is designed to utilize multiple technologies ... commercial scale.  Through the use of the latest ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3
... The U.S. Food and Drug Administration today is ... because the highest approved dose--80 milligram (mg)--has been associated ... particularly during the first 12 months of use. ... agency is recommending that simvastatin 80 mg be used ...
... Neurologix, Inc. (OTCBB: NRGX) announced today several new results ... its novel, investigational gene therapy NLX-P101 for the treatment ... presentation of study findings to the National Institutes of ... analysis of new data showed patients treated with NLX-P101 ...
Cached Medicine Technology:FDA Announces New Safety Recommendations for High-Dose Simvastatin 2FDA Announces New Safety Recommendations for High-Dose Simvastatin 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 2Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 4Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 5Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 6Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 7Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 8Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 9
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac® 100cc low suction evacuator kits with flat drains and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: